Cue Biopharma, Inc. (NASDAQ:CUE - Get Rating) - Equities research analysts at Oppenheimer boosted their FY2022 earnings estimates for shares of Cue Biopharma in a research report issued on Tuesday, November 15th. Oppenheimer analyst M. Breidenbach now anticipates that the company will post earnings of ($1.44) per share for the year, up from their previous forecast of ($1.54). Oppenheimer currently has a "Outperform" rating and a $10.00 target price on the stock. The consensus estimate for Cue Biopharma's current full-year earnings is ($1.41) per share. Oppenheimer also issued estimates for Cue Biopharma's Q4 2022 earnings at ($0.33) EPS, Q4 2022 earnings at ($0.33) EPS, FY2022 earnings at ($1.44) EPS, Q1 2023 earnings at ($0.27) EPS, Q2 2023 earnings at ($0.30) EPS, Q2 2023 earnings at ($0.30) EPS, Q4 2023 earnings at ($0.32) EPS, FY2023 earnings at ($1.20) EPS, FY2023 earnings at ($1.20) EPS, FY2024 earnings at ($1.08) EPS, FY2024 earnings at ($1.08) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($1.21) EPS.
Cue Biopharma Price Performance
Shares of NASDAQ:CUE opened at $3.68 on Thursday. Cue Biopharma has a 1 year low of $2.18 and a 1 year high of $16.95. The firm has a fifty day moving average price of $2.92 and a 200 day moving average price of $3.08. The company has a current ratio of 6.04, a quick ratio of 8.29 and a debt-to-equity ratio of 0.18.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. Amalgamated Bank bought a new stake in Cue Biopharma during the first quarter worth about $25,000. Delphia USA Inc. acquired a new position in Cue Biopharma in the second quarter valued at approximately $25,000. Newbridge Financial Services Group Inc. lifted its holdings in Cue Biopharma by 200.0% in the second quarter. Newbridge Financial Services Group Inc. now owns 12,000 shares of the company's stock valued at $30,000 after buying an additional 8,000 shares during the period. Ensign Peak Advisors Inc lifted its holdings in Cue Biopharma by 72.7% in the second quarter. Ensign Peak Advisors Inc now owns 17,960 shares of the company's stock valued at $45,000 after buying an additional 7,560 shares during the period. Finally, Mirabella Financial Services LLP acquired a new position in Cue Biopharma in the first quarter valued at approximately $58,000. Institutional investors and hedge funds own 39.95% of the company's stock.
Cue Biopharma Company Profile
Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to firstname.lastname@example.org.
Before you consider Cue Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cue Biopharma wasn't on the list.
While Cue Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here